Edesa Biotech Toekomstige groei
Future criteriumcontroles 0/6
Edesa Biotech's earnings are forecast to decline at 32.7% per annum. EPS is expected to grow by 16.6% per annum.
Belangrijke informatie
-32.7%
Groei van de winst
16.6%
Groei van de winst per aandeel
Biotechs winstgroei | 27.1% |
Inkomstengroei | n/a |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 20 Aug 2024 |
Recente toekomstige groei-updates
Recent updates
Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely
Aug 04We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate
Mar 10Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%
Sep 30Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans
Sep 23Edesa says mid-stage trial for anti-allergic cream reached full enrollment
Sep 07Edesa Biotech GAAP EPS of -$0.37 beats by $0.06
Aug 12Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth
May 16Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD
Apr 18Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation
Dec 08Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients
Sep 22Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation
Aug 27Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study
Jun 18Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?
Apr 13Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)
Feb 19Edesa Biotech receives C$14M for COVID-19 study
Feb 02Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans
Dec 08Edesa Biotech EPS misses by $0.04, beats on revenue
Dec 07Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment
Nov 03Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
9/30/2026 | N/A | -14 | N/A | N/A | 1 |
9/30/2025 | N/A | -11 | N/A | N/A | 2 |
9/30/2024 | N/A | -8 | N/A | N/A | 2 |
6/30/2024 | N/A | -7 | -5 | -5 | N/A |
3/31/2024 | N/A | -7 | -6 | -6 | N/A |
12/31/2023 | N/A | -8 | -6 | -6 | N/A |
9/30/2023 | N/A | -8 | -7 | -7 | N/A |
6/30/2023 | N/A | -9 | -11 | -11 | N/A |
3/31/2023 | N/A | -13 | -12 | -12 | N/A |
12/31/2022 | N/A | -16 | -11 | -11 | N/A |
9/30/2022 | N/A | -18 | -12 | -12 | N/A |
6/30/2022 | N/A | -18 | -7 | -7 | N/A |
3/31/2022 | N/A | -17 | -7 | -7 | N/A |
12/31/2021 | N/A | -15 | -14 | -14 | N/A |
9/30/2021 | N/A | -13 | -14 | -14 | N/A |
6/30/2021 | 0 | -12 | -15 | -15 | N/A |
3/31/2021 | 0 | -9 | -13 | -13 | N/A |
12/31/2020 | 0 | -8 | -7 | -7 | N/A |
9/30/2020 | 0 | -6 | -5 | -5 | N/A |
6/30/2020 | 1 | -5 | -5 | -5 | N/A |
3/31/2020 | 1 | -5 | -6 | -6 | N/A |
12/31/2019 | 1 | -4 | -6 | -6 | N/A |
9/30/2019 | 0 | -3 | -5 | -5 | N/A |
6/30/2019 | 0 | -3 | -4 | -4 | N/A |
3/31/2019 | N/A | -2 | -1 | -1 | N/A |
12/31/2018 | N/A | -2 | -1 | -1 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: EDSA is forecast to remain unprofitable over the next 3 years.
Winst versus markt: EDSA is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: EDSA is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: Insufficient data to determine if EDSA's revenue is forecast to grow faster than the US market.
Hoge groei-inkomsten: EDSA is forecast to have no revenue next year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if EDSA's Return on Equity is forecast to be high in 3 years time